臺灣博碩士論文加值系統

憂鬱不只是一個問題和現象而已，它更是真實的一種疾病，帶給患者一種破壞性的傷害。Venlafaxine HCl 是最新的抗憂鬱藥品，藥理學上是屬於SNRI (Serotonin/Norepinephrine Reuptake Inhibitor)藥品，在焦慮與憂鬱症之療效上及安全性皆受到重視，市場上頗受精神科醫師與病人的歡迎。
本研究旨在以製劑學技術，將高水溶性之Venlafaxine HCl製成每顆含75 mg (Venlafaxine base)緩釋膠囊，將可此藥的投遞次數從每天三次減為每天一次，以增進病人之用藥順從性，因此將可維持病人穩定的治療效果。
　在本製劑的製程中，以HPMC、Avicel為主要賦形劑，經過混合、擠壓、製粒、搓圓等步驟製成圓粒，以aquacoat ECD30為主要包衣原料。包衣後經充填至膠囊。但在製作之前，先以分子量相近且易溶於水之
B 1作為預試材料。所製成膠囊再依中華藥典第五版之規定，進行重量差異、均一度分析與在三種酸鹼度(pH 1.2、pH 4.5及pH 6.8)溶離媒液中之溶離試驗，其緩釋原理為擴散作用。結果顯示其重量差異為321.46 ± 0.59 mg (n=10；CV=0.18%)；均一度含量試驗為87.29 ± 3.16 mg (Venlafaxine HCl ; n=10; CV=3.62%)；在pH 1.2、pH 4.5及pH 6.8之溶離媒液中與原廠藥”Efexor 75mg XR”比較溶離相似度(F2值；N=3)，結果分別為79.2、76.25及56.34。在製粒過程之中，需要加入酒精及A成分之混合液當溶劑，才易完成製粒。aquacoat ECD30 需要包衣兩次才能達到緩釋效果。由所得各種數據推論，本研究所產製的「Venlafaxine HCl」緩釋膠囊應與原廠藥”Efexor 75mg XR”在溶離試驗中相似。

The depression is not only a problem and phenomenon but also a real disease. It brings a destructive injury to patients. Venlafaxine is the newest anti-depression medicine. In the pharmacology, it is a kind of SNRI (Serotonin/Norepinephrine Reuptake Inhibitor) medicine. Due to its curative effect of the depression and safety on the anxious, it is very popular to doctors of psychiatric units and patients in the market.
This research studied the technology of making high water soluble Venlafaxine HCl into a sustained release capsule containing 75 mg Venlafaxine base pellets. This would reduce the use of this medicine from three times per day to once. Therefore, the treatment of a patient would be more acceptable.
In the pellet preparation, Avicel acted as the main excipient and via mixing, extrusion, rounding to form the pellets. Finally, a capsule was filled with these pellets after they were coated with aquacoat ECD30. B 1 hydrochloride was used as a testing ingredient in the beginning as it is cheaper, water-soluble and has a similar molecular weight with venlafaxine. According to the fifth edition of pharmacopoeia in Taiwan, the weight variation and the dissolution test in three different pH values (pH 1.2, 4.5, and 6.8) of these capsule were carried. The average weight is 321.46 ± 0.59 mg (n =10; CV =0.18%) and equivalent to venlafaxine base 87.29 ± 3.16 mg (Venlafaxine HCl; n =10; CV =3.62%). The comparison of dissolution profiles with the brand name product Efexor 75mg XR shows the f2 values to be 79.2 , 76.25 and 56.34 respectively for pH 1.2、pH 4.5 and pH 6.8 environment. Therefore, it can be concluded that this product of Venlafaxine HCl should be similar to the original brand name product " Efexor 75mg XR " in the dissolution profile.

中文摘要 ……………………………………………………I
英文摘要 ……………………………………………………III
目錄………………………………………………………….V
表目錄……………………………………………………….VII
圖目錄……………………………………………………… IX
縮寫表.………………………………………………………XI
第一章緒論...............................................................................1
第一節 前言……………………………………………1
第二節 憂鬱症治療 ……………………………………2
第三節 藥物的控制釋放 ………………………………6
第四節 METHOCEL 的特性 …………………………9
第五節 Aquacoat ECD…………………………………14
第六節 研究目的 ………………………………………17
第二章 材料與方法 …………………………………………18
第一節 材料……………………………………………18
第二節 儀器……………………………………………19
第三節 實驗方法及步驟………………………………21

第三章 結 果………………………………………………32
第四章 討 論………………………………………………57
第五章 結 論………………………………………………68
參考文獻……………………………………………………70

1.楊寶峰。抗抑鬱藥。藥理學。2004; 18 : 237--246。
2.陳長安。抗憂鬱劑。常用藥品治療手冊。2002; 24：335-353。
3.蘇仕倩，戴淑華。新一代抗憂鬱劑Venlafaxine。成醫雜誌。2005。
4.Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression. J Psychopharmcol. 1994; 8:238-249.
5.Mary AG, Glen LS, Janet YA. Venlafaxine: 2003 Update. Clin Ther. 2003; 8:2138-2154.
6.Elingrod VL, Perry PJ. Venlafaxine : A heterocyclic antidepressant. Am J Hosp Pharm. 1994;51:3033-3046.
7.Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride:Analysis of the clinical trials database. J Clin Psychopharmacol. 1996; 16:54S-61S.
8.Feighner JP. Overview of antidepressants currently used to treat anxiety disorders. J Clin Psychiatry. 1999; 60(Suppl 22):18-22.
9.Parker G, Roy K, Wihelm K, Mitchell P. Assessing the comparative effectiveness of antidepressant therapies: A prospective clinical practice study. J Clin Psychiatry. 2001; 62:117-125.
10.Dikrran N, Marion R, Frank K, elt. Production information Efexor. PDR.2005; 59:3321-3333.
11.Thase ME, Entsuah ARM, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001; 178:234-241.
12.Stahl SM. Why settle for silver when you can go for gold? Response vs. recovery as the goal of antidepressant therapy. J Clin Psychiatry. 1999; 60:213-214.
13.Kelsey JE. Clinician perspective on achieving and maintaining remission in depression. J Clin Psychiatry. 2001; 62(Suppl 26):16-21.
14.Scott J, Teasdale JD, Paykel ES, et al. Effects of cognitive therapy on psychological symptoms and social functioning in residual depression. Br J Psychiatry. 2000; 177:440-446.
15.Entsuah AR, Huang H, Thasse Me. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001; 62:869-877.
16.Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. Br J Psychiatry. 2002; 180:396-404.
17.Guelfi JD, Ansseau M, Timmerman L, Korsgaard S. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol. 2001; 21:425-431.
18.Nierenberg AA. Do some antidepressants work faster than others？ J Clin Psychiatry. 2001; 62(Suppl 15):22-25.
19.Blier P. Possible neurobiological mechanisms underlying faster onset of antidepressant action. J Clin Psychiatry. 2001; 62(Suppl 4):7-11.
20.Montigny C, Silverstone PH, Debonnel G, et al. Venlafaxine in treatment-resistant major depression: A Canadian multi-center open-label trial. J Clin Psychopharmacol. 1999; 19:401-406.
21.Schweitzer I, Burrows G, Tuckwell V, et al. Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol. 2001; 21:185-189.
22.Binghe W, Teruna S, Richard AS. Physicochemical properties, formulation, and drug delivery. Drug delivery principles and application. 2005; 4:57-71.
23.Tapash K, Bhaskara R. Oral controlled release solid dosage forms. Theory and practice of contemporary pharmaceutics. 2005.,11:333—366.
24.林山陽。緩釋性膜衣包覆材料與處方設計。膜衣包覆技術。1996 : 6 ;175-214。
25.Shah V P, Tsong Y, Sathe P. In vitro dissolution profie comparison statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15:889-696.
26.Moore J W, Flanner H H. Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm Tech. 1996;20(6):64-74.
27.Abhijit V G, Kamlesh P O, Ali R. Study of release matrix formulation of a highly soluble drug. Controlled release society annual meeting.2005; 7.
28.Jayanti N, Jun H W, Price J C, Park M O. Controlled-release matrix tablets of ibuprofen using cellulose ethers and carrageenans: effect of formulation factors on factors on dissolution rates. Eup J of pharmaceutics and bio-pharmaceutics. 2005;61:56-68.
29.Sapna N, Pradeep R. Once daily sustained release tablets of venlafaxine, a novel antidepressant. Eup J of pharmaceutics and bio-pharmaceutics. 2002;54:9-15.
30. Aulton M E. Tablet. Pharmaceutics the science of dosage form design. 2000 ; 37: 616-628.
31.Aulton M E. Tablet. Pharmaceutics the science of dosage form design. 2000 ; 18: 304-321.
32. 江建良。統計資料之分析解釋。統計學。2001：4；69-98。